The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 16, 2026 for Aayush Agrawal, ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts more than Nifty Midcap 150 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ajanta Pharma promoter Aayush Agrawal (trustee of Aayush Agrawal Trust) has created a pledge on 1,49,000 shares of the company, which equals 0.12% of the total share capital. The pledge was created on February 11, 2026, with Bajaj Financial Securities Ltd as the pledgee, and the stated reason is to increase a loan. With this new pledge, Aayush Agrawal's total encumbered holding rises from 80,99,407 shares (6.48%) to 82,48,407 shares (6.60%) of the company. The disclosure was filed under Regulations 31(1) and 31(2) of SEBI's SAST Regulations, 2011, and includes shareholding details of other promoters such as Gabs Investments, Yogesh Agrawal Trust, Rajesh Agrawal Trust, and Ravi P Agrawal Trust. Overall encumbrance by the promoter group remains modest and well below concerning levels.
The pledge size is small at just 0.12% of shares, and total promoter encumbrance stays low at 6.60%, so this is largely a routine disclosure with limited impact on the stock. Investors may view any pledge creation with mild caution as it indicates the promoter is raising debt against shares, but the scale here is not material.